Endothelial-Cell-Derived Human Secretory Leukocyte Protease Inhibitor (SLPI) Protects Cardiomyocytes against Ischemia/Reperfusion Injury.
Cell Death
/ drug effects
Cell Line
Cytoprotection
Endothelial Cells
/ metabolism
Humans
Intracellular Space
/ metabolism
MAP Kinase Signaling System
Myocardial Reperfusion Injury
/ metabolism
Myocytes, Cardiac
/ metabolism
Oxygen
/ metabolism
Proto-Oncogene Proteins c-akt
/ metabolism
Reactive Oxygen Species
/ metabolism
Secretory Leukocyte Peptidase Inhibitor
/ metabolism
p38 Mitogen-Activated Protein Kinases
/ metabolism
anti-protease
cardiomyocytes
cardioprotection
endothelial cells
ischemia/reperfusion injury
protease inhibitor
secretory leukocyte protease inhibitor
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
31 10 2019
31 10 2019
Historique:
received:
26
09
2019
revised:
30
10
2019
accepted:
30
10
2019
entrez:
6
11
2019
pubmed:
7
11
2019
medline:
4
9
2020
Statut:
epublish
Résumé
Vascular endothelial cell (EC)-derived factors play an important role in endothelial-cardiomyocyte crosstalk and could save cardiomyocytes (CMs) from injury. The manipulation of endothelial cells to secrete protective factors could enhance cardioprotection. Secretory leukocyte protease inhibitor (SLPI) has been known to protect the heart. The goal of this study was to evaluate the in vitro paracrine protective effect and mechanisms of EC-derived human SLPI on cardiomyocytes subjected to hypoxia/reoxygenation (H/R) injury. Stable endothelial cells overexpressing human SLPI were generated from an endothelial cell line (EA.hy926). The cytoprotective effect was determined by cell survival assay. The results showed that endothelial-derived recombinant human SLPI (rhSLPI) reduced simulated ischemia/reperfusion (I/R)-(81.75% ± 1.42% vs. 60.27% ± 2.52%,
Identifiants
pubmed: 31683729
pii: biom9110678
doi: 10.3390/biom9110678
pmc: PMC6920779
pii:
doi:
Substances chimiques
Reactive Oxygen Species
0
Secretory Leukocyte Peptidase Inhibitor
0
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
p38 Mitogen-Activated Protein Kinases
EC 2.7.11.24
Oxygen
S88TT14065
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
J Mol Cell Cardiol. 2005 Oct;39(4):709-17
pubmed: 16140323
J Biol Chem. 2010 Jan 29;285(5):2968-75
pubmed: 19996096
Nat Med. 2011 Nov 07;17(11):1391-401
pubmed: 22064429
Pharm Biol. 2015;53(12):1831-41
pubmed: 25880145
Exp Ther Med. 2017 Dec;14(6):5793-5800
pubmed: 29285123
Physiol Rev. 2003 Jan;83(1):59-115
pubmed: 12506127
J Clin Invest. 2014 Sep;124(9):4039-51
pubmed: 25105365
J Biol Chem. 2004 Dec 3;279(49):51141-7
pubmed: 15385548
Cytokine Growth Factor Rev. 2016 Apr;28:79-93
pubmed: 26718149
Am J Cardiol. 2010 Aug 1;106(3):360-8
pubmed: 20643246
Gene Ther. 2001 Dec;8(24):1833-9
pubmed: 11821936
J Biol Chem. 2005 Jan 7;280(1):669-76
pubmed: 15492008
Chin Med J (Engl). 2007 May 5;120(9):777-81
pubmed: 17531118
J Mol Cell Cardiol. 1997 Sep;29(9):2383-91
pubmed: 9299362
J Transplant. 2012;2012:928954
pubmed: 22530110
Arterioscler Thromb Vasc Biol. 2016 Jan;36(1):145-55
pubmed: 26586663
PLoS One. 2012;7(6):e39633
pubmed: 22745797
Ann N Y Acad Sci. 1997 Dec 15;832:311-21
pubmed: 9704059
PLoS One. 2013 Jul 22;8(7):e70088
pubmed: 23894596
Biochem Biophys Res Commun. 2015 Nov 20;467(3):595-601
pubmed: 26367177
Circulation. 2001 Aug 7;104(6):705-10
pubmed: 11489779
Basic Res Cardiol. 2001 May-Jun;96(3):227-36
pubmed: 11403416
Am J Transplant. 2008 Apr;8(4):773-82
pubmed: 18294346
Am J Physiol Heart Circ Physiol. 2018 Apr 01;314(4):H812-H838
pubmed: 29351451
Int J Surg. 2009 Dec;7(6):490-8
pubmed: 19540944
Biomol Concepts. 2018 May 4;9(1):17-32
pubmed: 29729136
Scand J Infect Dis. 2012 Aug;44(8):615-9
pubmed: 22339655
Vasc Dis Prev. 2010;7:1-14
pubmed: 25558187
Braz J Med Biol Res. 2001 Jan;34(1):1-7
pubmed: 11151023
J Physiol. 2019 Feb 28;:null
pubmed: 30816576
J Endocrinol. 2014 Aug;222(2):289-99
pubmed: 24895416
J Extra Corpor Technol. 2004 Dec;36(4):391-411
pubmed: 15679285
J Mol Cell Cardiol. 2011 Nov;51(5):803-11
pubmed: 21791217
Toxicol Res. 2014 Sep;30(3):141-8
pubmed: 25343007
Exp Ther Med. 2018 Jun;15(6):5231-5242
pubmed: 29904407
Cell Physiol Biochem. 2015;35(5):1808-20
pubmed: 25833118
J Biol Chem. 2017 Aug 4;292(31):12787-12800
pubmed: 28637870
Am J Transl Res. 2016 Feb 15;8(2):765-77
pubmed: 27158368
Sci Rep. 2018 Oct 26;8(1):15885
pubmed: 30367147